Company / Cost of Revenue
Halozyme Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$228.8M
FY2025
5-year range
$45.5M / $228.8M
FY2021-FY2025
Trend
+43.5%
vs FY2024
Sector context
#33 of 85
Health Care
What the data says
At $229M, Halozyme's cost of revenue ranks #53 of 85 in the Health Care sector. Cost of Revenue has fluctuated over the past 10 years, ranging from $10M in FY2020 to $229M in FY2025.
Based on SEC 10-K filings.
$229M in FY2025 with a 5-year CAGR of +86.5%.
Increased from $192M to $229M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +18.0%
- 5-Year CAGR
- +86.5%
- 10-Year CAGR
- -
Sector benchmark
#53 of 85 in Health CareTop 61% of 85This company $228.8M Sector average $2.0B
▼
-88.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +86.5%, indicating consistent growth.
- In FY2025, cost of revenue increased 43.5% year-over-year.
- Ranks #33 out of 85 companies in the Health Care sector.
- Lowest cost of revenue in the period was in FY2020.
Company context
Key Data Points
- Strong profit margin: 47.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 118.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $228.8M | +43.5% |
| FY2024 | $159.4M | -17.1% |
| FY2023 | $192.4M | +38.1% |
| FY2022 | $139.3M | +205.9% |
| FY2021 | $45.5M | +349.3% |
| FY2020 | $10.1M | -67.5% |
| FY2019 | $31.2M | +207.3% |
| FY2018 | $10.1M | -67.5% |
| FY2017 | $31.2M | +37.0% |
| FY2016 | $22.7M | +263.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026